Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations
Complete Title: NAUTIKA1: MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB, ENTRECTINIB, VEMURAFENIB PLUS COBIMETINIB, OR PRALSETINIB IN PATIENTS WITH RESECTABLE STAGES II-III NON-SMALL CELL LUNG CANCER WITH ALK, ROS1, NTRK, BRAF V600, OR RET MOLECULAR ALTERATIONS
Trial Phase: II
Investigator: Renato Martins, MD, MPH
This trial will evaluate the efficacy and safety of targeted therapies in participants with resectable Stage IIA, IIB, IIIA, and select IIIB (T3N2) resectable and untreated non-small cell lung cancer (NSCLC) tumors with selected molecular alterations.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Renato Martins, MD, MPH
RG1121641
NCT04302025
NAUTIKA1: MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB, ENTRECTINIB, VEMURAFENIB PLUS COBIMETINIB, OR PRALSETINIB IN PATIENTS WITH RESECTABLE STAGES II-III NON-SMALL CELL LUNG CANCER WITH ALK, ROS1, NTRK, BRAF V600, OR RET MOLECULAR ALTERATIONS
Lung Carcinoma, Non-Small-Cell (NSCLC)